Advancement in New Treatments for Dengue: BRIM Biotechnology strategic collaboration with Johnson Et JohnsonInnovation.

摘要

Astrategic collaborative work to meet public health demand in Asia for Dengue treatment. TAIPEI - BRIM Biotechnology, Inc. ("BRIM"), announced it has entered a Collaboration, Option and License Agreement with Janssen Pharmaceutica N.V. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson ft Johnson. Under the agreement, which was facilitated by Johnson ft Johnson Innovation, the parties will pursue the research, development and commercialization of certain compounds identified by Janssen that are targeted for dengue indications.